Literature DB >> 12643608

Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.

A B R Thomson1, S Appleman, M Keelan, J L Wallace.   

Abstract

Previous studies have shown that the bisphosphonates (BP) vary in their damaging effect on the gastric mucosa, and endoscopy scores (erosions or erosions plus ulcers) after 1 and 2 weeks use of BP were significantly lower in H. pylori-positive versus -negative subjects. The mechanism of this damaging effect of BP and the interaction with H. pylori is unknown. As part of a separately reported study of the incidence of gastric damage after 2 weeks of treatment of healthy female postmenopausal volunteers with risedronate (5 mg/day) or alendronate (10 mg/day), gastric aspirates were taken at the time of the baseline esophagogastroduodenoscopy (EGD), and again at 1 and 2 weeks after daily intake of a BP At the time of the third EGD, when the volunteers had been on risedronate or alendronate for 2 weeks, antral biopsies were taken from normal-appearing mucosa. Gastric juice and antral biopsies were assessed for their concentration of the cytokines interleukin-la (IL-1alpha), IL-8, IL-13, and epidermal growth factor (EGF). H. pylori, the use of BP, and development of gastric mucosal lesions had no effect on gastric mucosal concentrations of IL-1alpha, IL-13, or EGF. In contrast, the concentration of IL-8 in antral mucosal biopsies of volunteers given BP for 2 weeks was higher in the presence than in the absence of an H. pylori infection and was increased further in those who develop lesions associated with the use of BP. There was no correlation between gastric mucosal and gastric juice concentrations of IL-8. Gastric juice concentrations of IL-8 and EGF were not affected by H. pylori status, the use of BP, or the development of lesions. However, gastric juice concentrations of IL-1alpha were numerically lower in those who were negative for H. pylori with no mucosal lesions (Hp-L-), intermediate in those who were H. pylori-negative with lesions (Hp-L+), and highest in those who were positive for H. pylori and had lesions (Hp+L+). The gastric juice concentration of IL-13 was threefold higher in the absence than in the presence of H. pylori, and the relative abundance of IL-13 was: Hp-L- >Hp-L+ >Hp+L(-1) >Hp+L+. The prostaglandin E2 concentration in gastric antral biopsies was similar in the four groups and was unchanged with the in vitro biopsy incubation with celecoxib. We speculate that the higher gastric endoscopy scores observed with the use of BP in H. pylori negative as compared with H. pylori positive individuals is due to their lower mucosal concentration of IL-8 as well as the lower gastric juice concentration of IL-1alpha and higher concentration of IL-13.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12643608     DOI: 10.1023/a:1021979510860

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Interleukin-8 activity correlates with histological severity in Helicobacter pylori-associated antral gastritis.

Authors:  T Ando; K Kusugami; M Ohsuga; M Shinoda; M Sakakibara; H Saito; A Fukatsu; S Ichiyama; M Ohta
Journal:  Am J Gastroenterol       Date:  1996-06       Impact factor: 10.864

2.  Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa.

Authors:  L M Lichtenberger; J J Romero; G W Gibson; M A Blank
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

3.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole.

Authors:  D J Hetzel; J Dent; W D Reed; F M Narielvala; M Mackinnon; J H McCarthy; B Mitchell; B R Beveridge; B H Laurence; G G Gibson
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

4.  Alendronate induces gastric injury and delays ulcer healing in rodents.

Authors:  S N Elliott; W McKnight; N M Davies; W K MacNaughton; J L Wallace
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

5.  Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients.

Authors:  P Gionchetti; D Vaira; M Campieri; J Holton; M Menegatti; A Belluzzi; E Bertinelli; M Ferretti; C Brignola; M Miglioli
Journal:  Am J Gastroenterol       Date:  1994-06       Impact factor: 10.864

6.  Prostaglandin biosynthesis by gastric mucosa. II. Studies in man.

Authors:  D R McCready; J L Wallace; M M Cohen
Journal:  Clin Biochem       Date:  1984-06       Impact factor: 3.281

7.  Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis.

Authors:  J E Crabtree; T M Shallcross; R V Heatley; J I Wyatt
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

8.  Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection.

Authors:  J E Crabtree; P Peichl; J I Wyatt; U Stachl; I J Lindley
Journal:  Scand J Immunol       Date:  1993-01       Impact factor: 3.487

Review 9.  Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease.

Authors:  J E Crabtree; I J Lindley
Journal:  Eur J Gastroenterol Hepatol       Date:  1994-12       Impact factor: 2.566

10.  Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying.

Authors:  A Robert; A S Olafsson; C Lancaster; W R Zhang
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

View more
  3 in total

1.  Concentrations of alpha- and beta-defensins in gastric juice of patients with various gastroduodenal diseases.

Authors:  Yoshito Nishi; Hajime Isomoto; Hiroshi Mukae; Hiroshi Ishimoto; Chun-Yang Wen; Akihiro Wada; Ken Ohnita; Yohei Mizuta; Ikuo Murata; Toshiya Hirayama; Masamitsu Nakazato; Shigeru Kohno
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  Prospective multi-center trial for the efficacy of ecabet sodium on the relief of dyspepsia in korean patients with chronic gastritis.

Authors:  Hak Yang Kim; Ki-Baik Hahm; Myung-Gyu Choi; Jong-Sun Rew; Sang-Young Seol; Hoon-Jai Chun; Oh-Young Lee; Weon-Seon Hong
Journal:  J Clin Biochem Nutr       Date:  2007-11       Impact factor: 3.114

3.  Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Zsuzsa Réka Dömötör; Nóra Vörhendi; Lilla Hanák; Péter Hegyi; Szabolcs Kiss; Endre Csiki; Lajos Szakó; Andrea Párniczky; Bálint Erőss
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-10       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.